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662Late-Onset Hemorrhagic Cystitis in Children after
Hematopoietic Stem Cell Transplantation for
Thalassemia and Sickle Cell Anemia: A Prospective
Evaluation of Polyoma (BK) Virus Infection and
Treatment with Cidofovir
Javid Gaziev,1 Pierpaolo Paba,2 Roberto Miano,3 Stefano Germani,3 Pietro Sodani,1
Pierluigi Bove,3 Carlo Federico Perno,2 Marco Marziali,1 Cristiano Gallucci,1 Antonella Isgro`,1
Katia Paciaroni,1 Andrea Roveda,1 Maria Domenica Simone,1 Gioia De Angelis,1
Cecilia Alfieri,1 Guido Lucarelli1Little is known about late-onset hemorrhagic cystitis (HC) in children, its relationship to BK virus, and treat-
ment with cidofovir (CDV) following hematopoietic stem cell transplantation (HSCT). We prospectively in-
vestigated BK virus reactivation in children who underwent HSCT from a matched related donor for
thalassemia or sickle cell anemia following busulfan-cyclophosphamide–based conditioning regimens and an-
alyzed risk factors for development of HC and its treatment with CDV. Grade 2-4 HC occurred in 30 patients
with a cumulative incidence of 26% (95% confidence interval [CI]5 18%-34%). The cumulative incidences of
BK viruria and viremia were 81% (95% CI5 69%-89%) and 28% (95% CI5 18%-40%), respectively. Multivar-
iate analysis revealed that use of antithymocyte globulin (ATG) (hazard ratio [HR]5 10.5; P5.001), peak BK
viruria.100,000 copies/mL (HR5 6.2; P5.004), and grade II-IVacute graft-versus-host disease (HR5 5.3; P
5 .007) were predictive factors for HC. Nineteen patients with HC were given CDVat 1.5 mg/kg/day 3 times
a week, or 5 mg/kg/week. The median duration of therapy was 27 days (range, 21-180 days), and a median of 9
doses were given (range, 6-22). All patients had a complete clinical response (CCR), and 69% had a microbi-
ological response at 4 weeks. Eleven patients with BK virus–related HC receiving supportive care also had
CCR. The median duration of HC in these patients was similar to that in patients treated with CDV. None
of the patients with HC cleared BK viruria when CCR was achieved. We conclude that late-onset HC is
more prevalent in children with sustained high BK viruria who are treated with ATG or who develop graft-
versus-host disease. Randomized clinical trials are urgently needed to better define the role of CDV in treating
BK virus–related HC.
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Hemorrhagic cystitis (HC) is one of the major
complications of hematopoietic stem cell transplanta-
tion (HSCT), causing significant morbidity and pro-
longed hospitalization. The urologic manifestations
vary from asymptomatic hematuria to bladder pain
with irritative voiding and/or severe bladder hemor-
rhage leading to clot retention and renal failure. The
overall incidence of HC has been reported to vary
between 7% and 68% [1-3]. Early-onset HC usually
occurs during or immediately after high-dose cyclo-
phosphamide (Cy) administration as part of the condi-
tioning regimen, whereas late-onset HC develops
beyond 1 week after transplantation, usually related
to an infectious cause. The reported incidence of
Biol Blood Marrow Transplant 16:662-671, 2010 663Late-Onset Hemorrhagic Cystitis in Thalassemia and Sickle Cell Anemialate-onset HC varies between 10% and 22% [4-6]. BK
virus (BKV) is most frequently associated with late-
onset HC [4-8], although adenovirus- and cytomegalo-
virus (CMV)-associated HC also occur [9,10].
BKV is a polyomavirus belonging to the Polyoma-
viridae family. Primary BKV infection occurs during
childhood, resulting in almost-universal seropositivity
[11]. Following primary infection, the virus remains la-
tent in the renourinary tract as the epidemiologically
most relevant latency site, as well as in the lung, liver,
brain, lymphocytes, and probably other tissues [12].
Reported seroprevalence rates in adults range between
60% and 90% [12,13]. Initial studies identified a qual-
itative association between BKV and HC [2,7,14]. Re-
cently introduced quantitative polymerase chain
reaction (PCR) techniques allow the determination
of BKV DNA load in urine and/or blood samples in
HSCT recipients; most studies to date have confirmed
a quantitative association between BK viruria and HC,
with patients with HC having higher viral loads in the
urine and blood [15-18]. About 50% of HSCT recip-
ients with persistent BK viruria do not develop HC,
however, indicating that other factors contribute to
this complication [2,16]. Most of these studies were
performed in heterogeneous adult populations with
hematologic malignancies to date, the role of BKV in
the development of HC in children, especially those
with nonmalignant diseases, has not been evaluated.
Furthermore most studies detected the virus at the
time of cystitis, therefore not allowing estimation of
the relationship between BK reactivation and HC.
Treatment of HC varies depending on severity.
The current standard of care for HC is symptomatic
and includes analgesia, hyperhydration, forced diure-
sis, and bladder irrigation to prevent clot formation
and renal failure. When conservative measures fail or
bleeding is intractable and life-threatening, surgical
intervention is considered. Various topical agents,
including alum, formalin, prostaglandin E1, and hy-
perbaric oxygen, have been used with controversial re-
sults, because of the absence of controlled studies. To
date, no antiviral drug with proven efficacy against BK
replication has been approved for use. Cidofovir
(CDV) is a cytosine derivative of an acyclic nucleo-
side-phosphonate analogue with broad-spectrum ac-
tivity against many DNA viruses, including CMV,
adenoviruses, and polyomaviruses [19]. CDV has
been used to treat BKV–related nephropathy in lim-
ited renal transplantation recipients [20] and bone
marrow (BM) transplantation recipients [21,22], with
variable results.
In the present study, we tested the hypothesis that
BKV reactivation alone is not sufficient to cause late-
onset HC, and the presence of coexisting risk factors
is required. To investigate this hypothesis, we prospec-
tively monitored BKV in urine and blood through
quantitative PCR assays in a homogeneous patientpopulation treated with a busulfan-Cy (BuCy)- based
conditioning regimen. We also studied the efficacy
of CDV for treatment of HC. To the best of our
knowledge, this is the first study to evaluate the inci-
dence of BKV, its potential role in the development
of HC, risk factors for HC, and the efficacy of CDV
therapy in children undergoing HSCT for thalassemia
and sickle cell anemia (SCA).PATIENTS AND METHODS
Patients
All patients who had thalassemia or SCA and un-
derwent HSCT from an HLA-matched family donor
were eligible for this study. Patients aged .17 years
and who received an HLA-mismatched transplant
were excluded from the analysis. The institutional re-
view board approved the treatment protocol, and all
parents or patients provided written informed consent,
in accordance with the Declaration of Helsinki.
Between July 2004, and March 2009, 117 patients
with thalassemia (n 5 107) and SCA (n 5 10) who re-
ceived a BM graft from anHLA-matched family donor
were enrolled in this study. Seven patients underwent
a second transplantation from the same donor. All
but 4 patients received unmanipulated BM as the
stem cell source; those 4 patients received unmanipu-
lated peripheral blood stem cells. The median patient
age was 8 years (range, 1.7-17 years); the median donor
age was 9.9 years (range, 1.8-53 years). Twenty-nine
patients had undergone splenectomy before HSCT.
The vast majority of the patients had severe iron over-
load, and most patients demonstrated some degree of
liver fibrosis at the time of transplantation. On the ba-
sis of 3 risk factors (hepatomegaly .3 cm, presence of
liver fibrosis, and irregular chelation history), patients
with thalassemia are categorized into 3 risk classes.
Class 1 patients have no risk factors, class 2 patients
have 1 or 2 risk factors, and class 3 patients have all 3
risk factors. These risk classes are not applicable to pa-
tients with SCA. Patient and transplant characteristics
are summarized in Table 1.Conditioning Regimens and GVHD Prophylaxis
Conditioning regimens used were all BuCy-based
(Table 1). Based on our experience, very young
patients (aged\4 years), patients who receive a BM
graft from a phenotypically identical donor, and pa-
tients with SCA have an increased rejection rate
when conditioned with a BuCy-based regimen alone.
Therefore, we added thiotepa (TT) or antithymocyte
globulin (ATG; Thymoglobulin; Genzyme, Lyon,
France) to the conditioning regimen of these sub-
groups of patients, in an attempt to decrease the rejec-
tion rate. Fifty-nine patients (50%) received TT and
Table 1. Patient and Transplant Characteristics
Variable
Number of patients 117
Sex, M/F, n 67/50
Age, years, median (range) 8 (1.7-17)
Diagnosis, n
Thalassemia 107
Sickle cell anemia 10
Risk class, n
Class 1/class 2/class 3 19/38/50
Not applicable 10
Red blood cell units received
before transplantation, median (range)
79 (2-307)
Serum ferritin, ng/mL, median (range) 1974 (279-10,222)
Liver iron, mg/g dry weight, median (range) 13 (0.6-48)
Aspartate aminotransferase, IU/L, median (range) 32 (13-216)
Alanine aminotransferase, IU/L, median (range) 35 (3-224)
Bilirubin, mg/dL, median (range) 1.1 (0.4-5.5)
Splenectomy, n 29
Liver fibrosis score (Ishak et al. [23]
staging score 0-6), median (range)
1 (0-5)
Not evaluable, n 8
HLA-identical siblings, n 106
HLA phenotypically identical parents or relatives, n 11
ABO blood group compatibility,
identical/mismatched, n
75/42
CMV serostatus, positive/negative, n 100/17
Stem cell source, n
Bone marrow 113
Peripheral blood 4
Conditioning regimen, n
Bu/Busilvex/Cy 200 23
Bu/Busilvex/TT 10/Cy 200 25
Bu/Busilvex/Cy 160 preceded
by HU, AZA, and Flu
28
Bu/Busilvex/TT 10/Cy 160 preceded
by HU, AZA, and Flu
15
Bu/Busilvex/TT 10/Cy 200/ATG 10
preceded by HU, AZA, and Flu
17
Bu/Busilvex/Cy 200/ATG 10 9
GVHD prophylaxis, n
CsA+ methylprednisolone 0.5
mg/kg + short MTX
56
CsA + methylprednisolone 0.5
mg/kg + Cy 7.5 mg/kg (d +1) + short MTX
61
Nucleated cell dose,  108/kg, median (range) 4.6 (1.3-20.8)
CD34+ cell dose,  106/kg, median (range) 7.1 (0.8-35)
CD3+ cell dose,  106/kg, median (range) 53 (3.8-330)
MTX indicates methotrexate; CsA, cyclosporine A; Bu, busulfan; TT,
thiotepa; HU, hydroxyurea; AZA, azathioprine; Flu, fludarabine.
664 Biol Blood Marrow Transplant 16:662-671, 2010J. Gaziev et al.26 patients (22%) received ATG. ATG was given at
a dose of 2-2.5 mg/kg/day for 4 or 5 days before trans-
plantation. Sixty-nine patients (59%) with advanced
thalassemia (risk class 3) or receiving a transplant
from a phenotypically identical family donor or a
second transplant received cytoreduction/immuno-
suppression with hydroxyurea 30 mg/kg and azathio-
prine 3 mg/kg daily from day -45 pretransplantation,
and fludarabine 20-30 mg/m2 from day -16 through
day -12 before the conditioning regimen. Starting in
June 2006, all patients received targeted i.v. Busilvex
(Pierre Fabre Medicament, Boulogne Billancourt,
France; target area under the curve, 900-1350 mmol/
min) instead of oral Bu. GVHD prophylaxis consisted
of cyclosporine, methylprednisolone, and a short
course of methotrexate. Diagnosis of acute GVHD(aGVHD) and chronic GVHD was based on standard
clinical criteria, with histopathological confirmation
when possible. Patients received a stem cell infusion
36 hours after the last dose of Cy.
Prophylaxis Against HC
Prophylaxis against HC consisted of sodium 2-
mercaptoethane sulfonate administration with 120%
of the daily Cy dose in 6 divided doses, starting imme-
diately before each dose ofCy. Patients received i.v. hy-
dration at 3000 mL/m2/24 hours beginning 14 hours
beforeCy administration and continuing until 24 hours
after the last dose of Cy, along with forced diuresis and
alkalization of the urine. During Cy administration,
a Foley catheter was placed to ensure immediate drain-
age of bladder and hence decrease bladder exposure to
acrolein in all patients.
Diagnosis of HC
Patients who had early HC (occurring within 1
week post-HSCT) were excluded from the analysis.
Only patients with late-onset HC (occurring beyond
1 week post-HSCT) were analyzed in this study. The
maximum severity of HC was graded according to
published criteria: grade 0, no hematuria; grade 1, mi-
croscopic hematuria; grade 2, macroscopic hematuria;
grade 3 macroscopic hematuria with clots; grade 4,
macroscopic hematuria with clots and impaired renal
function secondary to urinary tract obstruction. A di-
agnosis of HC required the presence of clinically sig-
nificant hematuria (grade 2-4) along with dysuria or
lower abdominal pain (or both). The worst clinical
presentation was considered the maximum grade.
Sampling of Specimens
Midstream urine and blood samples for BKV and
adenovirus were collected immediately before initiation
of the conditioning regimen, and then weekly thereafter
until at least 100 days post-HSCT. Microscopic urinal-
ysis and examination for microscopic or macroscopic
hematuria were performed on all midstream urine spec-
imens 3 times weekly during hospitalization and twice
weekly after discharge.WhenHCdeveloped, urine sam-
ples also were investigated for CMV. A total of 1267
urine and blood samples were obtained from 64 patients
(10-50 samples/patient).
PCR for BKV DNAQuantification in Serum and
Urine Samples
Before August 2006, qualitative PCR for BK viru-
ria was performed on urine samples in 15 patients who
developed HC. Between August 2006, and August
2009, PCR for BK DNA detection was performed in
plasma and urine samples from 64 patients. Urine
and blood samples were collected on the same day.
Qualitative PCR was performed in the first 9 patients,
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formed in the subsequent 55 patients. DNA from
plasma and urine samples was extracted using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany).
BKV DNA quantification was performed by real-
time TaqMan PCR using a commercial kit (BKV Q-
PCR Alert Kit; Nanogen Advanced Diagnostics, San
Diego, CA) for the detection of the target viral gene
encoding for large T-antigen of the BK virus with
the 7300 Real-Time PCR System (Applied Biosys-
tems, Foster City, CA). BK viral load sensitivity and
specificity were 100% and .95%, respectively.
Treatment of HC
The standard of care consisted of analgesia, hyper-
hydration, forced diuresis, and platelet transfusion to
maintain a platelet count at $50  109/L. Eleven pa-
tients who developed HC before the prospective trial
of CDV received standard supportive treatment.Nine-
teen patients with HCwere given CDV at a dose of 1.5
mg/kg/day 3 times a week or 5mg/kg/day once a week.
Probenecid, 1.25 g/m2 bymouth, was given 3 hours be-
fore and 1 hour and 8 hours after CDV administration.
Patients received i.v. hydration at 3 times maintenance
level, initiated 1 hour before and continuing until 1
hour after the completion of the drug infusion, fol-
lowed by hydration at 2 times maintenance level for
an additional 2 hours after CDV administration.
Supportive Care
Patients were given prophylactic broad-spectrum
antibiotics and antifungal drugs (amphotericin B prep-
arations) until the neutrophil level exceeded 1.0 109/
L. Patients also received oral nonabsorbable antifungal
nystatin and paromomycin for gut decontamination
from the start of conditioning regimen. Acyclovir
was administered for herpes virus, and trimethoprim/
sulfamethoxazole was given for Pneumocystis jiroveci
prophylaxis. All patients received i.v. immunoglobulin
at a dose of 250-500 mg/kg once weekly until day 100
post-HSCT for infection prophylaxis. All blood prod-
ucts were irradiated to 2500 cGy. CMV antigenemia
monitoring was done twice weekly at hematologic
recovery. Chimerism analysis was performed by
PCR-based analysis of short tandem repeats (Profiler
Plus; Applera, Foster city CA). In sex-mismatched
donor–recipient pairs, 2-color fluorescein in situ
hybridization also was performed according to stan-
dard procedures. Grade II or greater aGVHD was
treated with methylprednisolone 1-4 mg/kg/day.
Statistical Analysis
Data on pretransplantation patient characteristics,
transplant complications, and outcomes were prospec-
tively collected. The primary endpoint was grade 2-4
HC. Secondary endpoints were treatment-relatedmortality (TRM) and survival. Probabilities of HC,
TRM, and aGVHD and chronic GVHD were calcu-
lated using cumulative incidence curves to accommo-
date competing risks [24]. For HC, graft failure and
death without HC were considered as competing
events. Probabilities of survival and disease-free sur-
vival were calculated using the Kaplan-Meier estimator
[25].The effects of patient-, donor-, disease-, and treat-
ment-related variables on development of HC were
evaluated using cumulative incidence curves and com-
pared with the Gray test. Prognostic factors for the
occurrence of HC found to be significant or nearly
significant by univariate analysis were evaluated using
the proportional hazards model for competing-risk
regression analysis [26].The variables includeddiagno-
sis, patient age, donor type, conditioning regimen, use
of ATG in the conditioning regimen, donor–recipient
CMV serology, donor–recipient sex match, Cy dose,
seasonality, risk class, number of red blood cell units
received before transplantation, splenectomy, degree
of hepatomegaly, serum ferritin level, liver iron concen-
tration, second transplantation, early HC because of
drug toxicity, speed of neutrophil recovery, platelet
engraftment, presenceof aGVHD,BKviruria, BKvire-
mia, peak BK viruria, and viremia. All P values were 2-
sided, with P \.05 indicating statistical significance.
Statistical analyses were performed using StatView
5 (SAS Institute, Cary, NC) and R version 2.9.1 [27].RESULTS
A total of 99 patients experienced sustained engraft-
ment. Graft failure/rejection occurred in 8 patients
(n5 2 with primary graft failure; n5 6 with secondary
graft failure). The median time to neutrophil recovery
(defined as the first of 3 consecutive days on which
the neutrophil count exceeded 0.5  109/L) was 20
days (range, 12-43days), and themedian time to aplate-
let recovery (defined as the first of 7 consecutive days
that the platelet count exceeded 20  109/L without
platelet transfusion) was 23 days (range, 8-163 days).
Forty patients (34%) had grade II-IV aGVHD.
Clinical Course and Incidence of HC
Thirty of 117 patients developed clinically signifi-
cant (grade 2-4) late-onset HC within 1 year after
transplantation. The median time to onset of HC
was 38 days (range, 13-114 days), with only 1 patient
presenting after 100 days. In 1 patient, HC occurred
before platelet engraftment, and in the remaining 29
patients, HC developed more than 26 days after trans-
plantation. The median platelet count at the onset of
HC was 81  109/L (range, 2-274  109/L). Four
patients had grade 1 HC (without urinary symptoms),
24 patients had grade 2 HC, 2 patients had grade 3
HC, and 4 patients had grade 4 HC. Sixteen of the
Figure 1. Cumulative incidence of hemorrhagic cystitis.
Figure 2. Cumulative incidence of BK reactivation in urine and blood.
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aGVHD. In all but 2 of these patients, HC develop-
ment preceded GVHD, by a median of 23 days (range,
7-96 days). Ultrasound examination revealed bilateral
grade 3-4 hydronephrosis in the 4 patients with grade
4HC. All of these patients had impaired renal function
and moderate to severe flank pain poorly controlled
with repeated analgesic drugs, necessitating ureteral
stent placement. A contrast computed tomography
scan in 1 of these patients, who had severe intermittent
abdominal and flank pain, revealed bilateral grade 4
hydroureteronephrosis and left-sided ureteral stenosis.
This patient underwent retrograde stent placement on
the right side and antegrade stent placement through
percutaneous nephrostomy because of high-grade ob-
struction in the left ureter. In all 4 patients, the blood
creatinine level dropped to baseline level by the follow-
ing day, with complete resolution of flank pain. The
stents were removed 2-6 months later with no future
impairment of renal function in all 4 patients. The cu-
mulative incidence of grade 2-4 HC was 26% (95%
confidence interval [CI] 5 18%-34%), including
21% (95% CI 513%-28%) for grade 2 HC and 5%
(95% CI 5 2%-10%) for grade 3-4 HC (Figure 1).
Early HC occurred in 6 patients, with a cumulative in-
cidence of 5% (95%CI5 2%-10%). All these patients
had grade 2 HC with minor urinary symptoms that re-
solved within a few days with supportive care only, and
none subsequently developed late-onset HC.BKViruria and BKViremia
Nine of the 64 patients prospectively monitored
underwent qualitative PCR, and the remaining 55 pa-
tients underwent both qualitative and quantitative
PCR for BKV DNA. Sixty patients (94%) had at least
1 positive sample and 52 (81%) had 2 or more positive
samples for BK viruria. Thirty-four patients (53%) had
at least 1 positive sample and 18 (28%) had 2 or more
positive samples for BK viremia. Viruria and viremiawere defined as sustained in the presence of 2 or
more positive urine and plasma samples, and as tran-
sient otherwise. In 14 patients, the first BK viruria oc-
curred before HSCT, during conditioning; 9 of these
patients were in risk class 3 and had received precondi-
tioning chemotherapy with hydroxyurea, azathioprine,
and fludarabine. The median times to detection of sus-
tained BK viruria and BK viremia were 8.5 days (range,
0-60 days) and 11 days (range, 0-74 days), respectively.
BK viremia never occurred in the absence of viruria
and almost always followed BK viruria. The median
interval from the onset of viruria to the onset of vire-
mia was 19 days (range, 0-69 days). After the onset of
viruria, levels of BK viral DNA in the urine increased
progressively, with a median interval from onset to
peak level of 14 days (range, 0-146 days). The esti-
mated incidences of sustained BK viruria and BK vire-
mia were 81% (95% CI 5 69%-89%) and 28% (95%
CI 5 18%-40%), respectively (Figure 2). The median
numbers of peak viral copies in the urine and in the
blood were 21,363 copies/mL (range, 556-55  106
copies/mL) and 578 copies/mL (range, 556-16,480
copies/mL), respectively. The mean number of peak
viral copies in the urine was higher in patients who re-
ceived ATG compard with those who did not (44 106
copies/mL vs 17  106 copies/mL; P 5 .017, Mann-
Whitney test). All 30 patients with grade 2-4 HC
had BK viruria. Among the 52 patients with sustained
BK viruria, 15 (29%) developedHC. The median time
from peak BK viruria to development of HC was 15
days (range, 8-75 days). Thirteen of 26 patients
(50%) who had peak BK viruria .100,000 copies/
mL developed HC, compared with 2 of 27 patients
(7%) with peak BK viruria \100,000 copies/mL.
However, 10 patients with peak BK viruria between
6  106 and .55  106 copies/mL at 2 or more time
points did not develop HC. The 4 patients with grade
1 HC had BK viruria, whereas all of the other patients
without HC but with BK viruria had no microscopic
hematuria.
Figure 4. Cumulative incidence of hemorrhagic cystitis according to
BK viral load in the urine.
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known to lead toHC inHSCT recipients. In th 30 pat-
ents with HC, 2 patients had CMV and 1 patient had
adenovirus. The 2 patients who had CMV in the urine
also had simultaneous CMV reactivation in the blood,
hindering assessment of its contribution to HC. The
patient with simultaneous adenovirus in the urine had
persistent BK viruria of.55 106 copies/mL.The ad-
enovirus was not isolated from any other site (ie, blood,
feces, saliva) in this patient. CMV reactivation detected
by antigenemia occurred in 87% of the patients who
developed HC. Urine cultures obtained from patients
with HC were negative for bacterial infection.
Risk Factors
Univariate analysis revealed a significantly higher
prevalence of HC in patients who received ATG in
the conditioning regimen (Figure 3; P 5 .00001),
had peak BK viruria .100,000 copies (Figure 4;
P 5 .0009), or developed grade II-IV aGVHD (Fig-
ure 5; P 5 .014). In addition, patients aged .8 years
also had a higher incidence of HC, with a trend toward
significance (P 5 .056). None of the other variables
listed above was associated with the development of
HC. Multivariate analysis using the proportional haz-
ards model for competing-risk analysis confirmed the
prognostic importance of ATG (hazard ratio [HR] 5
10.5; P 5 .001), peak BK viruria (HR 5 6.2; P 5
.004), and aGVHD (HR 5 5.3; P 5 .007), but not of
patient age, for the development of HC (Table 2).
The cumulative incidence of HC in patients who had
all 3 adverse risk factors was 88% (95% CI 5 17%-
98%), compared with 64% (95% CI 5 27%- 86%),
30% (95% CI 5 12%-51%), and 0% in those with 2,
1, or none of these risk factors, respectively (Figure 6).
CDV Therapy
Two schedules of CDV therapy were used. At the
beginning of this prospective trial, in the first 10 pa-
tients we administered CDV 1.5 mg/kg/day 3 timesFigure 3. Cumulative incidence of hemorrhagic cystitis according to
use of ATG in the conditioning regimen.a week for at least 9 doses, because of toxicity concerns.
Once we saw that these patients exhibited no drug-
related nephrotoxicity, we gave the next 9 patients
CDV at a dose of 5 mg/kg/day once a week for the first
2 weeks, then once a week every other week thereafter.
Patients with grade 3-4 HCwere given 5 mg/kg/day of
CDV weekly for 4 consecutive weeks, followed by
biweekly administration. CDV was given until com-
plete resolution of HC. In patients with grade 3-4
HC, maintenance therapy with CDV was continued
until a.2 log decrease in urine viral load was detected.
Immunosuppressive prophylaxis against GVHD was
not modified in these patients. Patients with concom-
itant GVHD also were treated with steroids. The me-
dian time from onset of HC to start of CDV therapy
was 2 days (range, 0-34 days). In all but 4 patients,
CDV therapy was started as soon as the patient mani-
fested urologic symptoms.
The median duration of HC was 19 days (range,
10-53 days). The median duration of CDV therapy
was 27 days (range, 21-180 days), and a median of 9
doses were given (range, 6-22 doses). All patients
treated with CDV demonstrated a complete clinicalFugure 5. Cumulative incidence of hemorrhagic cystitis according to
grade II-IV acute GVHD.
Table 2. Proportional Hazards Model for Competing-Risk
Regression Analysis
Variable HR 95% CI P
ATG in the conditioning regimen 10.5 2.5-43 .001
Peak BK viruria 6.2 1.8-21 .004
GVHD 5.3 1.6-18 .007
ATG indicates antithymocyte globulin; GVHD, graft-versus-host disease.
668 Biol Blood Marrow Transplant 16:662-671, 2010J. Gaziev et al.response. Among the 13 evaluable patients, microbio-
logical response (defined as a 1-2 log decrease in viral
load) occurred in 5 patients (39%) at 2 weeks and in
9 patients (69%) at 4 weeks. However, none of
CDV-treated patients cleared BK viruria when a com-
plete clinical response was achieved. The median time
from clinical response to clearance of BK viruria was
74 days (range, 24-176 days). No patient experienced
HC recurrence after discontinuation of CDV. No dif-
ference in BK virus clearance was noted between the 2
different dosing schedules. CDV therapy was well tol-
erated, with no significant nephrotoxicity (data not
shown). Despite the adminstration of concurrent
nephrotoxic drugs (eg, cyclosporine, Prograf, ampho-
tericin B), no patient exhibited a significantly increased
serum creatinine level or discontinued therapy. Four
patients (21%) had transient mild proteinuria the day
after CDV administration. None of CDV-treated pa-
tients experienced bone marrow suppression resulting
in neutropenia. There was no correlation between
CDV dosage and renal toxicity. Ten patients with
grade 2 HC and 1 patient with grade 3 HC before
this prospective trial of CDV were treated with sup-
portive care. The median duration of HC in these pa-
tients was 11 days (range, 9-60 days), not significantly
different from that in the patients treated with CDV.
The CDV-treated patents included more cases of
grade 3-4 HC, however.
Survival and TRM
With amedian follow-up in survivors of 35months
(range, 5-61 months), 107 patients were alive, and 100Figure 6. Cumulative incidence of hemorrhagic cystitis according to
risk factors.of them were disease-free. One-year overall and
disease-free survival were 92% (95% CI 5 86%-
96%) and 85% (95% CI 5 78%-90%), respectively.
No patient died from HC. Three patients died within
the first 100 days post-HSCT, and 7 patients died
within 1 year post-HSCT. HC had no significant
impact on survival. Causes of death were GVHD
(n 5 6), infection (n 5 3), and posttransplantation
splenectomy (n 5 1).DISCUSSION
HC is a major complication in patients undergoing
HSCT. Current potent immunosuppressive treatment
protocols have significantly improved graft survival
and GVHD control in HSCT recipients, likely result-
ing in an increased rate of infection in these patients,
especially opportunistic viral reactivation. As opposed
to early-onset HC, which occurs during the condition-
ing regimen or within the first week of its completion
due to drug toxicity, laterHC is usually associated with
viral infections and frequently is more severe and occa-
sionally fatal [28,29]. The incidence of late-onset HC
in our patients was comparable to that reported previ-
ously in other pediatric patients [6,21].
There is accumulating evidence in the literature
supporting a strong association of BKV with urinary
tract pathology due to the urotropic nature of the virus
[2,7,11,30]. Further elucidation regarding the role of
BK virus infection in HC development in stem cell
transplant recipients is clearly needed. The association
between BKV and HC in BM transplantation recipi-
ents was first reported by Arthur et al. [7]. However,
most of the previous studies evaluating risk factors for
HC and its relationship to BKV were performed in ei-
ther small numbers of pediatric patients or in heteroge-
neous populations and involved different stem cell
sources and preparative regimens [6,21]. We prospec-
tively studiedBK viruria and viremia in a homogeneous
pediatric patient population treated with a BuCy-based
conditioning regimen, which allowed us to define the
role of BKV and risk factors for development of late-
onset HC in this context. This is the first study to eval-
uate the incidence of the BKV and its relationship to
HC in children with thalassemia and SCA. We found
that children with hemoglobinopathies have a high in-
cidence of BKV reactivation followingHSCT.The cu-
mulative incidences of sustained BKV reactivation in
the urine and in the blood were 81% and 28%, respec-
tively. BKV reactivation is associatedwith a failure ofT
cell immunity in HSCT recipients resulting from both
the conditioning regimen and immunosuppressive
prophylaxis against GVHD. In the present study, we
investigated the relationship between HC and CD3,
CD4, and CD8 lymphocyte recovery at 30 and 60
days post-HSCT.We found no statistically significant
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shown), suggesting that it is the number of BK virus–
specific cytotoxic T lymphocytes, not the absolute
number of lymphocytes, that plays an important role
in controlling BKV reactivation [31].
Our findings demonstrate that despite a high BKV
reactivation rate, especially in the urine, HC occurred
in only 29% of patients with sustained BK viruria.
This indicates that BKV infection is not specific or uni-
versal for HC and supports a more contributory role of
the virus in predisposed immunocompromised HSCT
recipients. In fact, 10 of our patients with persistently
higher BK viruria (between 6106 and.55 106 cop-
ies/mL) never developed HC, indicating that late-
onset HC is a multifactorial disease that requires other
cofactors for its development. These data are in line
with some previously published results [15,16,21]. Fur-
thermore, we found that high, but not persistent, BK
viral load in the urine is a risk factor for development
of HC, also in agreement with previous studies
[5,6,13,16,32]. Interestingly, BK viremia never oc-
curred in the absence of BK viruria and almost also
followed BK viruria. Neither persistent nor peak BK
viremia was associated with HC in our patients. This
contrasts with data reported by Erard et al. [18], who
showed that BK viremia detected during diseasewas in-
dependently associated with HC and that the higher
the viral load, the greater the risk of HC.
Inboth renal transplant andHSCTrecipients,more
intense immunosuppressionmay increase BKV replica-
tion in the urinary tract, leading to increased local in-
flammation and subsequent development of HC. In
the present study, the use ofThymoglobulin in the con-
ditioning regimen was strongly associated with HC in
both univariate and multivariate analyses (HR 5 10.5;
P5 .001). Thymoglobulin is known to be more potent
thanotherATGpreparations in preventing organ rejec-
tion [33]. An association between high Thymoglobulin
dose and increased infections has been reported previ-
ously [34]. Increased immunosuppression withThymo-
globulin increased viral replication with higher viral
loads in the urinary tract in our patients; mean peak
BK viruria was significantly higher in those receiving
Thymoglobulin compared with those not receiving
Thymoglobulin. Thus, we recommend careful viral
monitoring in patients treated with Thymoglobulin.
It has been suggested that an association between
GVHD and HC might exist, or that immunosuppres-
sive therapies used to treat GVHD increase the risk of
opportunistic infections, which subsequently cause
HC [32,35]. Nevertheless, some studies have failed
to show any correlation between GVHD and HC
[2,36]. In the present study, we found a higher rate of
HC in patients with grade II-IV aGVHD compared
with those with grade 0-I GVHD (HR 5 5.3; P 5
.007), suggesting that GVHD and/or its treatment
contribute to the increased risk of HC.Four of our patients developed hydronephrosis
with impaired renal function. To the best of our
knowledge, this is the first case series of ureteral
obstruction because of BK virus–relatedHC and resul-
tant ureteritis in pediatric HSCT recipients success-
fully resolved with stent placement. A similar case
has been reported in a young adult HSCT recipient
[37]. We stress the importance of ultrasonographic
renal monitoring in patients with HC for timely diag-
nosis of hydronephrosis, followed by ureteral stent
placement when necessary to prevent the development
of obstructive renal failure.
We also investigated coinfection with other
viruses, such as adenovirus and CMV, known to lead
to HC in HSCT recipients [9,10]. Urine and blood
samples also were prospectively evaluated by adenovi-
rus-specific PCR. Two of the 64 patients (3%) had ad-
enovirus in the urine, which was the only site in which
the virus was isolated. One of these patients had HC
along with persistently higher BK viruria. Although
it is unlikely, we cannot rule out a possible role of
adenovirus in the development of HC in this patient.
Treatment of late-onset HC remains a major ther-
apeutic challenge. Early and close collaboration be-
tween the transplantation physician and urologist is
essential for a successful outcome. There are no antivi-
ral drugs with proven efficacy for treating BKV–related
HC. CDV is currently the most selective antipolyoma-
virus agent [19], although the mechanism by which
CDV mediates is not clear, because unlike herpesvi-
ruses, polyomaviruses do not have viral-encoded
DNA polymerase. The experience with using CDV to
treat BK V infection comes from the renal transplanta-
tion setting, and nephrotoxicity has limited its use in
HSCT recipients, who typically are exposed to other
nephrotoxic drugs.To date, no prospective clinical trial
has evaluated the use of CDV in children and adoles-
cents with BK virus–related late-onset HC. In a recent
prospective case series, 22 pediatric HSCT recipients
with BKV/JC virus or adenovirus-associated HC were
given CDV 5 mg/kg twice weekly initially, then fort-
nightly, which resulted in complete eradication of the
virus from the blood, but not from urine [21].No neph-
rotoxicity was observed in these patients. Low-dose
CDV (1 mg/kg/week) without probenecid was given
to adults [22] and a small number of pediatric patients
[38]with the aimof avoiding nephrotoxicity and achiev-
ing higher urinary concentrations, with variable results.
In the present study, we prospectively treated 19 pa-
tients with CDV. These patients’ immunosuppressive
medications were not changed, because of concerns
about GVHD. Patients with HC and simultaneous
aGVHDwere treated with steroids. All patients recov-
ered from HC; however, none of them had cleared the
BKV from the urine by the time of complete resolution
of HC. Although BK viruria persisted, no patient expe-
rienced recurrence of HC after discontinuation of
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limiting nephrotoxicity or BM suppression resulting
in neutropenia observed. Interestingly, 11 patients
withHCbefore the clinical trial withCDVwere treated
with supportive care only, and all demonstrated com-
plete resolution of HC. The persistence of BK viruria
during CDV therapy and after resolution of HCmani-
festations, although with a decreased viral load, calls
into question the adequacy of CDV therapy for BKV–
related HC, because the most clinically appropriate
measurement of the efficacy of antiviral treatment is
clearance of virus and lack of progression to disease. In-
deed, in theHSCT setting, clinical resolution of adeno-
virus or CMV infection following CDV treatment is
associated with sustained clearance of these viruses
[39,40]. We do not know whether decreased BK viral
load translates into clinical improvement, however.
The presumed therapeutic effect in some patients,
whichmight be biased by a concomitant immune recov-
ery, together with the lack of known treatments and the
in vitro activity of CDV against BK virus, suggest the
need for further evaluation of CDV therapy for BK
virus–related HC.
In the present study, despite a higher rate of reac-
tivation of BKV in the urine in our HSCT recipients,
approximately one-third of the patients developed
BKV–related late-onset HC. These findings confirm
our hypothesis that higher urinary BK viral load is
not a sole risk factor for late-onset HC development,
and that other cofactors, such as ATG use and grade
II-IV aGVHD, contribute significantly to this compli-
cation. Multicenter prospective randomized trials are
needed to further define the role of CDV therapy in
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